“…11 In the last years, it has been considered the first-line option to treat pemphigus in developed countries. 1 Nevertheless, in Brazil, Rituximab has been prescribed as an exceptional option, for those cases of unresponsiveness to commoner drugs, 12 , 13 , 14 which encouraged us to look for a diverse treatment in order to decrease corticoid side effects when chronically prescribed. 9 , 10 …”